Pelthos Therapeutics Inc. cash flow statement

In fiscal 2025, Pelthos Therapeutics Inc.'s operations generated −$22.6m of cash; it spent $99,000 on capital projects, leaving free cash flow of −$22.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Pelthos Therapeutics Inc.: cash flow statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−6	−23	−42
Depreciation and amortisation	0	1	1
Stock-based pay	2	5	8
Capital spending	0	0	—
Free cash flow	−6	−23	—
Free cash flow after stock pay	−8	−28	—
Share buybacks	0	0	—
Shares issued	6	0	—

US$ millions unless shown otherwise. Fiscal quarters.

Pelthos Therapeutics Inc.: cash flow statement, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−1	−0	−15	−6	−13	−8
Depreciation and amortisation	0	0	0	0	0	0
Stock-based pay	0	0	2	2	2	3
Capital spending	0	0	—	—	0	0
Free cash flow	−1	−0	—	—	−13	−8
Free cash flow after stock pay	−1	−1	—	—	−15	−10

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BFRI vs PTHS CPIX vs PTHS IMCC vs PTHS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Pelthos Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pelthos Therapeutics Inc.